

Ken Ohmine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10278731/publications.pdf>

Version: 2024-02-01

70
papers

555
citations

759233

12
h-index

752698

20
g-index

71
all docs

71
docs citations

71
times ranked

833
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Complications Associated with Peripherally Inserted Central Catheters During Induction Chemotherapy for Acute Myeloid Leukemia. <i>Internal Medicine</i> , 2022, 61, 989-995.	0.7	3
2	Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis. <i>Leukemia Research</i> , 2022, 112, 106750.	0.8	1
3	Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome. <i>Internal Medicine</i> , 2022, 61, 3271-3275.	0.7	3
4	Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1694-1700.	1.3	2
5	Clinical interaction between dexamethasone and aprepitant in chemotherapy for lymphoma. <i>Annals of Hematology</i> , 2022, 101, 1211-1216.	1.8	2
6	Novel immunotherapies in multiple myeloma. <i>International Journal of Hematology</i> , 2022, 115, 799-810.	1.6	3
7	Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. <i>Blood</i> , 2022, 140, 594-607.	1.4	14
8	Identification of endoscopic factors that predict poor responses to steroids in patients with gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 963-967.	2.4	1
9	Clinical association between thyroid disease and immune thrombocytopenia. <i>Annals of Hematology</i> , 2021, 100, 345-352.	1.8	11
10	Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models. <i>PLoS ONE</i> , 2021, 16, e0245232.	2.5	5
11	Risk factors for high-dose methotrexate-induced nephrotoxicity. <i>International Journal of Hematology</i> , 2021, 114, 79-84.	1.6	12
12	The impact of overweight on renal toxicity in patients treated with dexamethasone, high-dose cytarabine, and cisplatin. <i>International Journal of Hematology</i> , 2020, 111, 396-400.	1.6	1
13	Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis. <i>Acta Haematologica</i> , 2020, 143, 250-259.	1.4	5
14	Evaluation of thrombotic events in patients with immune thrombocytopenia. <i>Annals of Hematology</i> , 2020, 99, 49-55.	1.8	9
15	Salvage Chemotherapy Followed by Autologous Stem-Cell Transplantation Using Targeted Busulfan for Refractory Diffuse Large B-Cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e92-e96.	0.4	3
16	Steep neutrophil recovery following unrelated bone marrow transplantation is a major risk factor for the development of acute graft-versus-host disease—a retrospective study. <i>Transplant International</i> , 2020, 33, 1723-1731.	1.6	5
17	Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. <i>International Journal of Hematology</i> , 2020, 112, 369-376.	1.6	1
18	Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma. <i>Annals of Hematology</i> , 2020, 99, 2893-2901.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Differential Localization and Invasion of Tumor Cells in Mouse Models of Human and Murine Leukemias. <i>Acta Histochemica Et Cytochemica</i> , 2020, 53, 43-53.	1.6	1
20	Dimethyl Fumarate Ameliorates Graft-Versus-Host Disease By Negatively Regulating Aerobic Glycolysis in Alloreactive T-Cells. <i>Blood</i> , 2020, 136, 24-25.	1.4	1
21	Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen Receptor. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 16-25.	4.4	10
22	Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index. <i>International Journal of Hematology</i> , 2019, 109, 470-476.	1.6	6
23	Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. <i>International Journal of Hematology</i> , 2019, 109, 141-146.	1.6	26
24	Predictive value of soluble interleukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy. <i>Annals of Hematology</i> , 2019, 98, 2121-2129.	1.8	3
25	TAFRO Syndrome with an Anterior Mediastinal Mass and Lethal Autoantibody-Mediated Thrombocytopenia: An Autopsy Case Report. <i>Acta Haematologica</i> , 2019, 141, 158-163.	1.4	4
26	Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1926-1933.	1.3	3
27	Alloreactive T Cells Display a Distinct Chemokine Profile in Response to Conditioning in Xenogeneic GVHD Models. <i>Transplantation</i> , 2019, 103, 1834-1843.	1.0	7
28	Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2019, 60, 734-741.	1.3	9
29	Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2019, 60, 703-710.	1.3	7
30	Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia. <i>Annals of Hematology</i> , 2019, 98, 1127-1133.	1.8	0
31	III. Chimeric Antigen Receptor T-cell Immure Therapy. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1375-1383.	0.0	0
32	Steep Neutrophil Recovery Following Unrelated Bone Marrow Transplantation Is a Major Risk Factor for the Development of Acute Graft-Vs-Host Disease. <i>Blood</i> , 2019, 134, 5686-5686.	1.4	0
33	Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (<i>FGFR1</i>) rearrangement. <i>Hematology</i> , 2018, 23, 470-477.	1.5	28
34	Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1563-1574.	2.0	24
35	A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH. <i>Cancer Genetics</i> , 2018, 220, 44-48.	0.4	3
36	Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2018, 107, 712-715.	1.6	7

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. <i>International Journal of Hematology</i> , 2018, 108, 499-509.	1.6	9
38	False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 812-814.	1.7	14
39	Comprehensive Analysis of Chemokines in Host Organs and Their Corresponding Receptors on Donor T-Cells in Xenogeneic Gvhd Model. <i>Blood</i> , 2018, 132, 5676-5676.	1.4	0
40	Alloantigen-Activated Human T-Cells Increase Extracellular Fatty Acid Uptake and Intracellular Lipid Metabolism during Xenogeneic Gvhd. <i>Blood</i> , 2018, 132, 3320-3320.	1.4	0
41	Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 316-323.	1.3	10
42	The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 357-364.	1.7	0
43	CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. <i>Hematology</i> , 2017, 22, 347-353.	1.5	16
44	Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2017, 96, 719-724.	1.8	9
45	Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. <i>Hematology</i> , 2017, 22, 521-526.	1.5	10
46	Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia. <i>International Journal of Hematology</i> , 2017, 106, 411-417.	1.6	2
47	Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2541-2547.	1.3	4
48	A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. <i>Leukemia Research</i> , 2016, 42, 82-87.	0.8	12
49	Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. <i>Annals of Hematology</i> , 2016, 95, 1513-1519.	1.8	20
50	Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations. <i>International Journal of Hematology</i> , 2016, 104, 446-453.	1.6	19
51	Comprehensive Analysis of Activation and Proliferation Kinetics and Effector Functions of Human Lymphocyte Subsets in Xenogeneic GvHD Model. <i>Blood</i> , 2016, 128, 3350-3350.	1.4	0
52	Intrathecal Administration of High-Titer Cytomegalovirus Immunoglobulin for Cytomegalovirus Meningitis. <i>Case Reports in Hematology</i> , 2014, 2014, 1-3.	0.4	4
53	Mechanisms of resistance to azacitidine in human leukemia cell lines. <i>Experimental Hematology</i> , 2014, 42, 294-306.e2.	0.4	40
54	CD25 Expression Is Associated with Inferior Clinical Outcomes in Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3678-3678.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Engineering of CD19-CAR T Cells from Non-Hodgkin Lymphoma Patients in a Closed System in Combination with Retronectin/OKT3 Stimulation. <i>Blood</i> , 2014, 124, 2446-2446.	1.4	0
56	Profiles Of De Novo CD25-Positive Mature B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 4308-4308.	1.4	1
57	Clinical Features of Newly Diagnosed CD25-Positive Follicular Lymphoma. <i>Blood</i> , 2012, 120, 1543-1543.	1.4	0
58	Overcoming Resistance to 5-Azacytidine in Acute Myelogenous Leukemia. <i>Blood</i> , 2012, 120, 1370-1370.	1.4	0
59	Clinical Features of De Novo CD25-Positive Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 2666-2666.	1.4	0
60	Incidental Carcinomas Detected by PET/CT Scans In the Patients with Malignant Lymphoma: A Single-Center Experience with 363 Patients. <i>Blood</i> , 2010, 116, 4132-4132.	1.4	0
61	Ectopic Expression and Role of RCAN1 in Myeloid Leukemia Cells.. <i>Blood</i> , 2009, 114, 1274-1274.	1.4	1
62	Vincristine Potentiates the Anti-Leukemia Effect of the Aurora Kinase Inhibitor VE-465 by Enhancing Apoptosis in Myeloid Leukemia Cells.. <i>Blood</i> , 2009, 114, 2762-2762.	1.4	0
63	Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. <i>International Journal of Hematology</i> , 2008, 87, 195-202.	1.6	16
64	Clinical Analysis of Adult Acute Leukemia with Rearrangements of the 11q23/MLL: Multicenter Co-Operative Study.. <i>Blood</i> , 2006, 108, 2354-2354.	1.4	0
65	Cloning and Characterization of a Tipifarnib-Resistant BCR/ABL-Positive Cell Line, K562/RR.. <i>Blood</i> , 2005, 106, 1527-1527.	1.4	0
66	Heme Affects Sensitivity to Imatinib through Regulation of Nrf2 Activity in BCR/ABL-Positive Cell Lines.. <i>Blood</i> , 2004, 104, 2092-2092.	1.4	0
67	Analysis of Gene Expression Profiles in an Imatinib-Resistant Cell Line, KCL22/SR. <i>Stem Cells</i> , 2003, 21, 315-321.	3.2	35
68	Stimulation of GATA-2 as a mechanism of hydrogen peroxide suppression in hypoxia-induced erythropoietin gene expression. <i>Journal of Cellular Physiology</i> , 2001, 186, 260-267.	4.1	28
69	Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. <i>Oncogene</i> , 2001, 20, 8249-8257.	5.9	74
70	A de novo Philadelphia chromosome-positive acute mixed-lineage leukemia with both major and minor BCR/ABL mRNA transcripts. <i>American Journal of Hematology</i> , 2000, 65, 72-74.	4.1	5